# A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins

Study · id `cardio:ct-nct02634151` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02634151](<https://clinicaltrials.gov/study/NCT02634151>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02634151

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

## Technical summary

Registry record NCT02634151. Randomized; quadruple masking; primary purpose treatment. Start 2016-11 (registry gives no type); primary completion 2017-06 (actual). Results posted on 2020-06-25.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 105 participants (enrolled count; ClinicalTrials.gov record NCT02634151, source copy `cardio:ctgov-nct02634151-2020-06-25`, retrieved 2026-10-31)
- Start date: 2016-11 (registry gives no type) (ClinicalTrials.gov record NCT02634151, source copy `cardio:ctgov-nct02634151-2020-06-25`, retrieved 2026-10-31)
- Primary completion: 2017-06 (actual) (ClinicalTrials.gov record NCT02634151, source copy `cardio:ctgov-nct02634151-2020-06-25`, retrieved 2026-10-31)
- Completion: 2017-08 (actual) (ClinicalTrials.gov record NCT02634151, source copy `cardio:ctgov-nct02634151-2020-06-25`, retrieved 2026-10-31)
- Results first posted: 2020-06-25 (ClinicalTrials.gov record NCT02634151, source copy `cardio:ctgov-nct02634151-2020-06-25`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT02634151, source copy `cardio:ctgov-nct02634151-2020-06-25`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02634151-2020-06-25`, retrieved 2026-10-31)

## The registry's words

- Brief title: A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins
- Acronym: ROYAL-1
- Condition: Hypercholesteremia
- Intervention (Drug): Gemcabene
- Intervention (Drug): Placebo
- Lead sponsor: NeuroBo Pharmaceuticals Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)

## Provenance

Content hash: 7a63dc1089e475d5f5a4b80b7b4eda29a256e08a89ed0610f7ef1b4758266c89
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
